See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Social Media
Stock Markets
Education
Donald Trump
Natural Disasters
Floods
Cryptocurrency
Music
Innovation
Bitcoin
Work
Published • loading... • Updated

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis

Summary by ophthalmologytimes.com
Krystal Biotech initiates EMERALD-1 trial for KB801, a redosable eye drop gene therapy.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

ophthalmologytimes.comophthalmologytimes.com

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis

Krystal Biotech initiates EMERALD-1 trial for KB801, a redosable eye drop gene therapy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ophthalmologytimes.com broke the news in on Monday, July 14, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal